AMGN
NASDAQ · Biotechnology
Amgen Inc
$415.21
-2.63 (-0.63%)
AMGN News29 articles
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
Wall Street Mixed as Weak Jobs Data Fuels Rate-Cut Bets, Nasdaq Leads
U.S. stocks opened mixed Friday as a surprising drop in July payrolls eased rate hike fears, boosting tech shares. The Nasdaq surged 1.3% while the Dow inched up, with Caterpillar weighing on blue chips.
Dow Hits Record as Three Stocks Drive Most of Gain
The Dow Jones Industrial Average closed at a record high, with Amgen, Goldman Sachs, and Nvidia driving 79% of the gain. The S&P 500 and Nasdaq fell.
Dow Advances as Tech Spending Bets Fuel Mixed Market Close
The Dow advanced on AI spending expectations, while the Nasdaq slipped. Amgen, Lilly, and Disney rose; SpaceX and AMD fell. Markets await Friday's jobs report.
Dow Hits Record as Three Stocks Drive Nearly a Third of Rally
The Dow Jones Industrial Average hit a record high, with Caterpillar, Amgen, and Nvidia accounting for nearly a third of the two-day advance. Friday's jobs report could test the rally's breadth.
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
Dow Rises 537 Points on Earnings-Driven Rotation into Value Stocks
The Dow Jones Industrial Average jumped 537 points on Tuesday, led by strong earnings from defensive and industrial stocks, while the Nasdaq slipped.
Dow Dips from Record as Nike and Amgen Weigh on Blue Chips
The Dow slipped from a record intraday high as Nike and Amgen weighed heavily, while tech stocks surged on Broadcom's Apple deal and AI momentum.
AbbVie Surges $17.8 Billion in Market Cap, Surpassing Apogee Deal Value
AbbVie shares soared 3.99% to $261.07, adding $17.8B in market value—more than the $10.9B Apogee deal. The stock now trades above analyst targets, setting up a key Q2 earnings report.
Dow Hits New Peak as Apple and Amgen Lift Blue Chips; Tech Stocks Falter
The Dow set a new record close on Thursday, propelled by Apple and Amgen, as AI and chip stocks declined. Soft labor data relieved Fed pressure.
Generate Biomedicines Shares Reclaim IPO Price After Heavy Trading Week
Generate Biomedicines (GENB) surged 13.7% in a week, closing Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as sector momentum lifts biotech stocks.
Dow Rebounds 930 Points as Oil Plunges After Trump Halts Iran Strikes
The Dow surged 930 points as oil prices dropped sharply after President Trump called off planned strikes on Iran, soothing geopolitical fears. Honeywell, Boeing, and Caterpillar led the gains.
Dow Rebounds on AI Buying, Hot PPI Data Keeps Fed Focus
The Dow Jones Industrial Average recovered 0.57% on Thursday as investors snapped up AI and chip stocks, but hotter-than-expected producer price data kept inflation and Fed rate worries alive.
SCHD's Heavy Top Holdings Raise Red Flags for Safety Seekers
SCHD's top 10 holdings now make up 43.5% of assets, raising concentration risk. With a 3.24% yield and $95.17B in assets, the fund's safety profile is under scrutiny.
Caterpillar Earnings Propel Dow's 700-Point Surge Amid Mixed Market Signals
The Dow Jones surged nearly 700 points midday Thursday, led by a 10% jump in Caterpillar shares after strong quarterly results, while tech stocks lagged amid inflation concerns.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.
SCHD ETF Boosts Healthcare in Rebalance as Dividend Fund Inflows Surge
The Schwab U.S. Dividend Equity ETF (SCHD) increased its healthcare allocation to 18.5% during its yearly portfolio update, adding Abbott Laboratories and UnitedHealth Group. The fund gathered nearly $4 billion in the first quarter as investors poured a total of $24.1 billion into U.S. dividend-focused funds, marking the strongest quarterly start since 2022.
SCHD ETF Gains Investor Attention Following Annual Rebalance and Dividend Payout
The Schwab U.S. Dividend Equity ETF (SCHD) is drawing renewed interest following its annual portfolio rebalance and a recent dividend distribution. The fund's strategic shift and income profile are being highlighted as key attractions for investors.
AbbVie Gains on $8 Billion Bond Sale, Outperforms Slumping Market
AbbVie shares climbed 3.29% to $232.08 on Friday, defying a broader market decline. The pharmaceutical giant is set to raise approximately $7.95 billion through a seven-part bond sale settling March 4.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Merck Shares Drop on Insider Sale, Investors Await Key FDA Decision
Merck & Co. stock fell 3.5% amid an executive share sale and underperformance versus a broader market rally. Traders are focused on an upcoming FDA ruling for Keytruda's ovarian cancer expansion.
Dow Holds 50,000 as Markets Await Key Jobs, Inflation Data
The Dow Jones Industrial Average edged up 17 points to 50,132.79, maintaining its position above the 50,000 threshold. Investors are focused on upcoming employment and inflation reports, which could influence Federal Reserve policy.
Amgen Shares Slide on FDA Setback and Enbrel Weakness, Pressuring Dow
Amgen stock fell nearly 2% Monday, pressured by an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% quarterly drop in Enbrel sales. The decline weighed on the price-weighted Dow Jones Industrial Average.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
Dow Retreats from 50K Milestone as Investors Await Inflation, Jobs Data
The Dow Jones Industrial Average edged lower Monday after its historic close above 50,000, while the S&P 500 and Nasdaq gained on tech strength. Markets are focused on upcoming inflation and employment reports.
Johnson & Johnson Shares Retreat Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 1.1% as healthcare stocks underperformed the broader market. Traders are eyeing upcoming U.S. jobs and inflation data for direction.
Dow Retreats Below 50,000 as Rotation Hits Tech; Key Economic Data Awaited
The Dow Jones Industrial Average fell below the 50,000 mark in Monday trading, pressured by a shift out of technology stocks. Investors await critical payrolls and inflation reports later this week.
Amgen Hits 52-Week Peak on Strong Earnings; Key Data, Dividend Date Ahead
Amgen shares surged 4.5% to a 52-week high of $384.32, fueled by robust quarterly results and a dividend declaration. Investors now await delayed U.S. jobs and inflation figures.
Amgen Reaches 52-Week Peak on Friday; Investors Eye Inflation Data and Drug Pricing
Amgen shares surged 4.5% to close at $384.32 on Friday, achieving a new 52-week high. Market participants are monitoring upcoming U.S. inflation figures and developments in drug pricing.